Picot D, Sandmeier E, Thaller C, Vincent M G, Christen P, Jansonius J N
Abteilung Strukturbiologie, Biozentrum der Univeristät Basel, Switzerland.
Eur J Biochem. 1991 Mar 14;196(2):329-41. doi: 10.1111/j.1432-1033.1991.tb15821.x.
Aspartate aminotransferase undergoes major shifts in the conformational equilibrium of the protein matrix during transamination. The present study defines the two conformational states of the enzyme by crystallographic analysis, examines the conditions under which the enzyme crystallizes in each of these conformations, and correlates these conditions with the conformational behaviour of the enzyme in solution, as monitored by a fluorescent reporter group. Cocrystallization of chicken mitochondrial aspartate aminotransferase with inhibitors and covalent coenzymesubstrate adducts yields three different crystal forms. Unliganded enzyme forms triclinic crystals of the open conformation, the structure of which has been solved (space group P1) [Ford, G. C., Eichele, G. & Jansonius, J. N. (1980) Proc. Natl Acad. Sci. USA 77, 2559-2563; Kirsch, J. F., Eichele, G., Ford, G. C., Vincent, M. G., Jansonius, J. N., Gehring, H. & Christen, P. (1984) J. Mol. Biol. 174, 487-525]. Complexes of the enzyme with dicarboxylate ligands form monoclinic or orthorhombic crystals of the closed conformation. The results of structure determinations of the latter two crystal forms at 0.44 nm resolution are described here. In the closed conformation, the small domain has undergone a rigid-body rotation of 12-14 which closes the active-site pocket. Shifts in the conformational equilibrium of aspartate aminotransferase in solution, as induced by substrates, substrate analogues and specific dicarboxylic inhibitors, can be monitored by changes in the relative fluoresence yield of the enzyme labelled at Cys166 with monobromotrimethylammoniobimane. The pyridoxal and pyridoxamine forms of the labelled enzyme show the same fluorescence properties, whereas in the apoenzyme the fluorescence intensity is reduced by 30%. All active-site ligands, if added to the labelled pyridoxal enzyme at saturating concentrations, cause a decrease in the fluorescence intensity by 40-70% and a blue shift of maximally 5 nm. Comparison of the fluorescence properties of the enzyme in various functional states with the crystallographic data shows that both techniques probe the same conformational equilibrium. The conformational change that closes the active site seems to be ligand-induced in the reaction of the pyridoxal form of the enzyme and syncatalytic in the reverse reaction with the pyridoxamine enzyme.
在转氨作用过程中,天冬氨酸转氨酶的蛋白质基质构象平衡会发生重大变化。本研究通过晶体学分析确定了该酶的两种构象状态,研究了酶在每种构象下结晶的条件,并将这些条件与酶在溶液中的构象行为相关联,该行为由荧光报告基团监测。鸡线粒体天冬氨酸转氨酶与抑制剂和共价辅酶底物加合物的共结晶产生了三种不同的晶体形式。未结合配体的酶形成开放构象的三斜晶体,其结构已得到解析(空间群P1)[福特,G.C.,艾歇尔,G.和扬松纽斯,J.N.(1980年)《美国国家科学院院刊》77,2559 - 2563;基尔希,J.F.,艾歇尔,G.,福特,G.C.,文森特,M.G.,扬松纽斯,J.N.,盖林,H.和克里斯汀,P.(1984年)《分子生物学杂志》174,487 - 525]。该酶与二羧酸盐配体的复合物形成封闭构象的单斜或正交晶体。本文描述了后两种晶体形式在0.44纳米分辨率下的结构测定结果。在封闭构象中,小结构域发生了12 - 14度的刚体旋转,从而封闭了活性位点口袋。由底物、底物类似物和特定二羧酸抑制剂诱导的溶液中天冬氨酸转氨酶构象平衡的变化,可以通过用单溴三甲基铵双马来酰亚胺标记在Cys166处的酶的相对荧光产率的变化来监测。标记酶的吡哆醛和吡哆胺形式表现出相同的荧光特性,而在脱辅酶中荧光强度降低了30%。如果以饱和浓度将所有活性位点配体添加到标记的吡哆醛酶中,会导致荧光强度降低40 - 70%,最大蓝移5纳米。将酶在各种功能状态下的荧光特性与晶体学数据进行比较表明,这两种技术探测的是相同的构象平衡。在酶的吡哆醛形式的反应中,封闭活性位点的构象变化似乎是由配体诱导的,而在与吡哆胺酶的逆反应中是同步催化的。